Market Scenario
The global CRISPR-CAS9 gene editing technologies market is expected to grow at a healthy CAGR of 14.6% during 2019-2026.
Gene editing is the modern biotechnological techniques designed to alter the genomes of living organisms for health or economic benefits. Now-a-days, gene editing isnot only used in the medical sector but also in agricultural sector. CRISPR/Cas9 is recently developed technology that is effectively and specifically changes genes within organisms. The global CRISPR/Cas9 gene editing market is majorly driven by increasing government funding for genomics projects, increasing application of genomics in medical field, and growing prevalence of infectious and genetic diseases. Additionally, rapid advancement in technology and increasing demand for genetically modified crops has fueled the growth of the market.
However, gene editing and research is a brainstorming process and requires skilled professionals. Additionally, high cost of research and long approval time for the products may slow the growth of the market.
Segmentation
The global CRISPR-CAS9 gene editing technologies market is segmented on the basis ofapplications and end users.
On the basis of application, the CRISPR-CAS9 gene editing technologies market is segmented intogenome engineering, disease models, RNA editing, knockdown/activation, and others. Genetic engineering is further segmented into medicine, agriculture, research, and other. Disease models is sub segmented into oncology, cardiology, CNS, infectious diseases, dermatology, metabolic & genetic diseases and others
On the basis of end users, the CRISPR-CAS9 gene editing technologies market is segmented into biotechnology & pharmaceutical companies, academic & government research institutes, and others.
Regional Analysis
The global CRISPR-CAS9 gene editing technologies market is segmented into America, Europe, Asia Pacific and the Middle East & Africa. America dominates the global market owing to the well-developed technology, government support and increasing demand for the new and advanced products for the treatment of the various diseases.
Europe accounts for the second leading CRISPR-CAS9 gene editing technologies market due to strong government support and availability of the funds for research. Asia Pacific is the fastest growing market owing to presence of huge opportunity for the development of the market. Additionally, presence of rapidly growing economy has fueled the market growth in this region.
On the other hand, the Middle East & Africa holds the least share in the CRISPR-CAS9 gene editing technologies market. Middle East holds the major share due to well developed technology and high spending on research.
Key Players
The key players in the CRISPR-CAS9 gene editing technologies market are: Thermo Fisher Scientific (U.S.), Merck & Co., Inc. (U.S.), Genscript (U.S.), Sangamo Therapeutics, Inc. (U.S.), Integrated DNA Technologies, Inc. (U.S.), Lonza (Switzerland), New England Biolabs (U.S.), CRISPR THERAPEUTICS (Switzerland), Mirus Bio LLC (U.S.), Takara Bio Inc. (Japan), Abbott Laboratories (U.S.), and Bio-Rad Laboratories, Inc. (U.S.).
Segmentation
Global CRISPR-CAS9 Gene Editing Technologies Market , By Application
Genome Engineering
Medicine
Agriculture
Research
Other
Disease models
Oncology
Cardiology
CNS
Infectious diseases
Dermatology
Metabolic and genetic diseases
Others
RNA editing
Knockdown/activation
Others
Global CRISPR-CAS9 Gene Editing Technologies Market , By End Users
Biotechnology & Pharmaceutical Companies
Academic & Government Research Institutes
Others
Major Companies In the market
Others
Thermo Fisher Scientific
Merck & Co., Inc.
Genscript
Sangamo Therapeutics, Inc.
Integrated DNA Technologies, Inc.
Lonza
New England Biolabs
CRISPR THERAPEUTICS
Mirus Bio LLC
Takara Bio Inc.
Abbott Laboratories
Bio-Rad Laboratories, Inc.
1. Introduction
1.1. Market Definition
1.2. Market Scope
2. Research Methodology
2.1. Primary Research
2.2. Secondary Sources
2.3. Assumptions & Exclusions
3. Market Overview
3.1. Research Report Segmentation & Scope
3.2. Value Chain Analysis
3.3. Key Market Trend Analysis
3.3.1. Market Drivers
3.3.2. Market Restraint/Challenges
3.3.3. Market Opportunities
3.4. Porter’s Five Forces Analysis
3.5. Potential Venture Avenues
3.6. Market Share Analysis, 2018
3.7. Pipeline Analysis
3.8. Regulatory Framework
3.9. Top Company Strategy
3.10. Cost Structure Analysis
4. Application Overview
4.1. Introduction
4.2. Market Size & Forecast, 2016 to 2026
4.2.1. Genome Engineering
4.2.1.1 Medicine
4.2.1.2. Agriculture
4.2.1.3. Research
4.2.1.4. Other
4.2.2. Disease models
4.2.2.2. Oncology
4.2.2.3. Cardiology
4.2.2.4. CNS
4.2.2.5. Infectious diseases
4.2.2.6. Dermatology
4.2.2.7. Metabolic and genetic diseases
4.2.2.8. Others
4.2.3. RNA editing
4.2.4. Knockdown/activation
4.2.5. Others
5. End Users Overview
5.2. Introduction
5.3. Market Size & Forecast, 2016 to 2026
5.3.1. Biotechnology & Pharmaceutical Companies
5.3.2. Academic & Government Research Institutes
5.3.3. Others
6. Regional Overview
6.2. Introduction
6.3. Market Size & Forecast, 2016 to 2026
6.3.1. Americas
6.3.1.2. North America
6.3.1.2.1. U.S.
6.3.1.2.2. Canada
6.3.1.3. South America
6.3.2. Europe
6.3.2.2. Western Europe
6.3.2.2.1. Germany
6.3.2.2.2. France
6.3.2.2.3. U.K.
6.3.2.2.4. Italy
6.3.2.2.5. Spain
6.3.2.2.6. Rest Of Western Europe
6.3.2.3. Eastern Europe
6.3.3. Asia Pacific
6.3.3.2. Japan
6.3.3.3. China
6.3.3.4. India
6.3.3.5. Australia
6.3.3.6. South East Asia
6.3.3.7. Rest of Asia Pacific
6.3.4. The Middle East & Africa
6.3.4.2. The Middle East
6.3.4.3. Africa
7. Manufacturer/ Vendor Profile
7.2. The following attributes will be considered while profiling key manufacturers in this industry:
7.2.1. Company Overview
7.2.2. Financial Synopsis
7.2.3. Recent Developments
7.2.4. R&D Investments (if any)
7.2.5. Strategy Overview (Analyst Perspective)
7.2.6. Product Portfolio
7.3. Companies Profiled
7.3.1. Thermo Fisher Scientific
7.3.2. Merck & Co., Inc.
7.3.3. Genscript
7.3.4. Sangamo Therapeutics, Inc.
7.3.5. Integrated DNA Technologies, Inc.
7.3.6. Lonza
7.3.7. New England Biolabs
7.3.8. CRISPR THERAPEUTICS
7.3.9. Mirus Bio LLC
7.3.10. Takara Bio Inc.
7.3.11. Abbott Laboratories
7.3.12. Bio-Rad Laboratories, Inc.
© 2019 Data N Analysis. All Rights Reserved | Design by Data N Analysis